TriSalus Life Sciences, Inc.
TLSI- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001826667
No open-market purchases or sales by TriSalus Life Sciences, Inc. insiders were filed in the last 90 days; 78 institutions reported holding it in 13F filings for Q2 2026, worth $99.0M in total; no superinvestor holds it.
Other share classesTLSIW
13F holders, Q1 2024
Institutional positions in TriSalus Life Sciences, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +6 vs. Q4 2023
- Shares held
- 926.0K
- +246.4K (+36.3%) vs. Q4 2023
- Total value
- $9.03M
- +$3.29M (+57.2%) vs. Q4 2023
- New holders
- 9
- 6 more added
- Sold out
- 3
- 5 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TLSI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 78 | $99.0M |
| Q1 2026 | 84 | $83.4M |
| Q4 2025 | 64 | $79.6M |
| Q3 2025 | 56 | $44.5M |
| Q2 2025 | 46 | $46.2M |
| Q1 2025 | 34 | $16.3M |
| Q4 2024 | 28 | $11.8M |
| Q3 2024 | 31 | $10.0M |
| Q2 2024 | 27 | $9.20M |
| Q1 2024 | 25 | $9.03M |
| Q4 2023 | 19 | $5.74M |
| Q3 2023 | 9 | $699.3K |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding TriSalus Life Sciences, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Duquesne Family Office LLCSuperinvestorDuquesne Family Office | 315,955 | $3.08M | 0.08% | +315,955 | New |
| Vanguard Group Inc | 167,159 | $1.63M | 0.00% | +2,023+1.2% | Added |
| Geode Capital Management, LLC | 134,099 | $1.31M | 0.00% | +8,337+6.6% | Added |
| Goldman Sachs Group Inc | 54,475 | $531.1K | 0.00% | +54,475 | New |
| Connecticut Wealth Management, LLC | 44,606 | $434.9K | 0.02% | −12,582−22.0% | Reduced |
| BlackRock Inc. | 42,170 | $411.2K | 0.00% | +40,900+3,220.5% | Added |
| Wetherby Asset Management Inc | 34,950 | $340.8K | 0.02% | 00.0% | Unchanged |
| Northern Trust Corp | 28,423 | $277.1K | 0.00% | +10,233+56.3% | Added |
| Anson Capital, Inc. | 24,415 | $238.0K | 0.34% | −10,590−30.3% | Reduced |
| Millennium Management LLC | 17,696 | $172.5K | 0.00% | +17,696 | New |
| Cambridge Investment Research Advisors, Inc. | 15,554 | $152.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 13,309 | $129.8K | 0.00% | +820+6.6% | Added |
| JPMorgan Chase & Co | 10,559 | $103.0K | 0.00% | +10,559 | New |
| Tyche Wealth Partners LLC | 10,000 | $97.5K | 0.02% | −16,664−62.5% | Reduced |
| Qube Research & Technologies Ltd | 5,490 | $53.5K | 0.00% | +5,490 | New |
| Bank of America Corp | 2,168 | $21.1K | 0.00% | +2,168 | New |
| Tower Research Capital LLC (TRC) | 1,542 | $15.0K | 0.00% | −431−21.8% | Reduced |
| Wells Fargo & Company | 1,319 | $12.9K | 0.00% | +2+0.2% | Added |
| Hoertkorn Richard Charles | 668 | $6.51K | 0.00% | 00.0% | Unchanged |
| GPS Wealth Strategies Group, LLC | 657 | $6.41K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 391 | $3.81K | 0.00% | −16,424−97.7% | Reduced |
| Signaturefd, LLC | 100 | $975 | 0.00% | +100 | New |
| Deerfield Management Company, L.P. (Series C) | 1 | $10 | 0.00% | 00.0% | Unchanged |
| Clear Street LLC | 1 | $10 | 0.00% | +1 | New |
| Macquarie Group Ltd | 291 | $3 | 0.00% | +291 | New |
| HC Advisors, LLC | 0 | $0 | 0.00% | −101,736−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −48,011−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −16,216−100.0% | Sold out |